MammaPrint® 70-gene Breast Cancer Recurrence Assay

The MINDACT Trial Results

MINDACT is a prospective, randomized, phase III, controlled clinical trial that investigates the clinical utility of MammaPrint, when compared to (or used in conjunction with) standard clinical pathological criteria, for the selection of patients unlikely to benefit from adjuvant chemotherapy. From 2007 to 2011, 6,693 women who had undergone surgery for early-stage breast cancer enrolled in the trial, across 112 centers in nine countries.

Results from the MINDACT Trial have been published in the New England Journal of Medicine.  

Click here to learn more about the MINDACT trial results


Prognostic and Predictive:  MammaPrint answers your Clinical Questions

MammaPrint can help you answer the most important clinical questions for the care and management of breast cancer patients:

  • Who is at risk for recurrence?
  • Does MammaPrint help identify which patients may safely forego chemotherapy?
  • What is the optimal treatment for each patient?

See the Validation and Clinical Utility sections below for more information

MammaPrint is the only breast cancer assay backed by peer-reviewed, prospective outcome data1

In the first ever prospective clinical study for a breast cancer recurrence assay, RASTER (MicroarRAy PrognoSTics in Breast CancER) confirmed the utility of the MammaPrint 70-gene signature to identify those breast cancer patients that may safely forgo chemotherapy.  As compared to standard clincopathological classification, MammaPrint re-stratified 20% of Clinical High Risk patients to Low risk.  97% of this Low Risk patient group which primarily chose to forgo chemotherapy, were disease free at 5 years.